

# Metadata of the chapter that will be visualized online

---

Series Title		
Chapter Title	Identification of Thioredoxin Target Protein Networks in Cardiac Tissues of a Transgenic Mouse	
Chapter SubTitle		
Copyright Year	2013	
Copyright Holder	Springer Science+Business Media New York	
Corresponding Author	Family Name	<b>Li</b>
	Particle	
	Given Name	<b>Hong</b>
	Suffix	
	Division	Department of Biochemistry and Molecular Biology
	Organization	UMDNJ-NJMS Cancer Center
	Address	205 South Orange Avenue, CC1105, 07103, Newark, NJ, USA
	Email	liho2@umdnj.edu
Author	Family Name	<b>Fu</b>
	Particle	
	Given Name	<b>Cexiong</b>
	Suffix	
	Division	
	Organization	
	Address	
	Email	
Author	Family Name	<b>Liu</b>
	Particle	
	Given Name	<b>Tong</b>
	Suffix	
	Division	
	Organization	
	Address	
	Email	
Author	Family Name	<b>Parrott</b>
	Particle	
	Given Name	<b>Andrew M.</b>
	Suffix	
	Division	
	Organization	
	Address	
	Email	

---

---

## Abstract

The advent of sensitive and robust quantitative proteomics techniques has been emerging as a vital tool for deciphering complex biological puzzles that would have been challenging to conventional molecular biology methods. The method here describes the use of two isotope labeling techniques—*isobaric tags for relative and absolute quantification* (iTRAQ) and *redox isotope-coded affinity tags* (ICAT)—to elucidate the cardiovascular redox-proteome changes and thioredoxin 1 (Trx1)-regulated protein network in cardiac-

specific Trx1 transgenic mouse models. The strategy involves the use of an amine-labeling iTRAQ technique, gauging the global proteome changes in Trx1 transgenic mice at the protein level, while ICAT, labeling redox-sensitive cysteines, reveals the redox status of cysteine residues. Collectively, these two quantitative proteomics techniques can not only quantify global changes of the cardiovascular proteome but also pinpoint specific redox-sensitive cysteine sites that are subjected to Trx1-catalyzed reduction.

---

Key words (separated by '-') Quantitative proteomics - Liquid chromatography - Tandem mass spectrometry - iTRAQ - Redox ICAT - Hypertrophy - Thioredoxin 1

---

## Identification of Thioredoxin Target Protein Networks in Cardiac Tissues of a Transgenic Mouse 2 3

Cexiong Fu, Tong Liu, Andrew M. Parrott, and Hong Li 4

### Abstract 5

The advent of sensitive and robust quantitative proteomics techniques has been emerging as a vital tool for deciphering complex biological puzzles that would have been challenging to conventional molecular biology methods. The method here describes the use of two isotope labeling techniques—*isobaric tags for relative and absolute quantification* (iTRAQ) and *redox isotope-coded affinity tags* (ICAT)—to elucidate the cardiovascular redox-proteome changes and thioredoxin 1 (Trx1)-regulated protein network in cardiac-specific Trx1 transgenic mouse models. The strategy involves the use of an amine-labeling iTRAQ technique, gauging the global proteome changes in Trx1 transgenic mice at the protein level, while ICAT, labeling redox-sensitive cysteines, reveals the redox status of cysteine residues. Collectively, these two quantitative proteomics techniques can not only quantify global changes of the cardiovascular proteome but also pinpoint specific redox-sensitive cysteine sites that are subjected to Trx1-catalyzed reduction. 6 7 8 9 10 11 12 13 14 15

**Key words** Quantitative proteomics, Liquid chromatography, Tandem mass spectrometry, iTRAQ, Redox ICAT, Hypertrophy, Thioredoxin 1 16 17


## 1 Introduction 18

Chemical labeling of peptides/proteins with isotope-coded reagents (1), rendering peptide/proteins with mass differences that are readily discernible in mass spectrometers, enables the comparative proteome quantitation from multiple biological samples. One advantage of the chemical-labeling technique is its versatile applicability to all sources of proteins (cells, tissues, serum, bone, hair, etc.). Unlike stable isotope labeling with amino acid in cell culture (SILAC) technique (2), which incorporates stable isotopic amino acids during cell culture, but is limited to proteins that can be retrieved from cultured cells that undergo rapid protein turnover. Here we will introduce the application of two distinct chemical-labeling approaches—iTRAQ (1, 3) and ICAT (4, 5)—to 19 20 21 22 23 24 25 [AU1] 26 27 28 29 30

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

quantify the proteome changes in left ventricular tissues of wild-type and a cardiac-specific Trx1 transgenic mouse model (6, 7).

iTRAQ reagents label the primary amines on the N-terminus and lysine residues of peptides and can accommodate the quantification of up to eight different samples simultaneously (8-plex iTRAQ (8)). The isobaric nature of iTRAQ reagents does not add to the complexity of chromatography and the mass spectrum (MS) and only releases signature fragments ( $m/z$  114–117 for 4-plex and 113–121 for 8-plex) of individual tags upon collision-induced dissociation that can be observed in tandem mass (MS/MS) spectra for peptide identification and quantification (Fig. 1a). On the other hand, ICAT reagents, available in light and heavy versions, label free thiol groups of cysteine residues. ICAT reagents incorporate a biotin tag to enable



**Fig. 1** Typical workflow for ICAT and iTRAQ quantitation. **(a)** In the iTRAQ workflow, protein samples are first subjected to TCEP reduction, MMTS alkylation, and trypsin digestion. The resulting tryptic peptides are then labeled by designated iTRAQ reagents separately. After quenching the reaction, labeled peptides are mixed and separated by multidimensional chromatography. Finally, MS data is acquired on a 4800 MALDI TOF/TOF in a data-dependent acquisition mode. **(b)** In the ICAT workflow, protein thiols are first labeled by either the light ICAT (*control*) or heavy ICAT (*Trx1*-overexpressing tissue) reagents. Protein disulfide bonds are then reduced by DTT and alkylated with IAM, sequentially. The labeled proteins are mixed, digested with trypsin and separated sequentially using SCX, avidin affinity, and RPLC separations. ICAT-labeled peptides are identified and quantified by a 4800 MALDI-TOF/TOF mass spectrometer. Peptides containing *Trx1*-reduced cysteines had an ICAT H/L ratio larger than one and can be quantified by the precursor peak intensity and identified by the MS/MS spectrum. Modified from Molecular & Cellular Proteomics, 2009 (8), 1674–1687 with permission.

selective avidin-based enrichment of ICAT-labeled peptides from non-cysteine-containing peptides, therefore reducing sample complexity. The light and heavy ICAT-labeled peptides appear as doublets in MS spectra, within which the peak intensity/integrated chromatographic peak area of the doublet are used for peptide quantitation. Peptide sequence is obtained from the MS/MS spectra of either the light or heavy ICAT-labeled peptide (Fig. 1b). Many derivatives of the ICAT technique were created to gauge the redox status of cysteines in peptides by introducing different reduction agents and workflows (5, 9, 10).

A general shotgun proteomics approach commonly deals with a massive number of tryptic peptides (20,000–100,000) in a single liquid chromatography coupled with a tandem mass spectrometer (LC/MS/MS) experiment (11). To maximize proteome coverage and discovery of low-abundant proteins, multiple chromatographic separations are routinely applied in conjunction with these chemical-labeling techniques for peptide fractionation and enrichment. Some of the most popular multidimensional chromatographic methods include multidimensional protein identification technology (MUDPIT) (12), OFFGEL (13, 14), strong cation exchange coupled with reversed phase liquid chromatography (SCX-RPLC) (3, 15, 16), and SCX-affinity chromatography-RPLC (5, 7). Here we will describe the application of the latter two techniques for the preparation of iTRAQ and ICAT-labeled peptides for LC/MS/MS identification and quantification of peptides and their reduction by Trx1.

Many lines of evidence (17, 18) have established Trx1, an 11 kDa antioxidant protein, as a negative regulator of oxidative stress-induced hypertrophy. Here we demonstrate a detailed proteomics method involving the use of two complementary stable isotope labeling proteomics techniques to identify the cardiac Trx1-targeted protein network in a Trx1 transgenic mouse model. By use of this protocol, we were able to identify 78 putative Trx1 reductive sites in 55 proteins (7), including many metabolic enzymes within the protein networks regulating the tricarboxylic acid (TCA) cycle and oxidative phosphorylation pathways that have been shown previously to be regulated by Trx1 (17). Some novel target protein networks, including the creatine–phosphocreatine shuttle, the mitochondrial permeability transition pore complex, and the cardiac contractile apparatus, were observed for the first time. By using the two comparative proteomics methods including iTRAQ and redox ICAT, we were able to find that Trx1 plays not only a conventional role as an antioxidant but also a role in remodeling the cardiovascular system to regulate cardiac energy dynamics and muscle contraction.

## 2 Materials

### 2.1 Tissue Homogenization and Protein Extraction

1. The left ventricular heart tissues from control and Trx1-overexpressed mice (three in each group) ~~are diced into 2×2 mm cubes and rinsed thoroughly by ice cold PBS (3×) to remove blood content.~~
2. ICAT Lysis Buffer: 6 M urea, 2 % CHAPS, 1 % Triton X-100, and 30 mM Tris-HCl at pH 7.5 and 0.1 % (v/v) of protease inhibitor cocktail (Sigma, cat no. P8340, St Louis, MO, USA) (see Note 1).
3. Omni Tissue Homogenizer: (Omni International Inc., Marietta, GA, USA).
4. ~~BCA~~ Protein Assay Kit: (Pierce, cat #. 23225, Rockford, IL, USA).
5. Spectra MAX 190 Microplate Spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
6. iTRAQ Lysis Buffer: 150 mM TEAB, 1.0 % Igepal CA630 (NP-40), 1.0 % Triton X-100, 0.1 % v/v protease inhibitor cocktail.

### 2.2 ICAT Labeling

1. Cleavable ICAT® Reagent—10 Assay kit (Sciex Cat# 4339036, Forster City, CA, USA).
2. Accessory for ICAT: Cartridge holder (4326688), needleport adaptor (4326689), outlet connector (4326690), avidin affinity cartridges (4326694), cation exchange cartridges (4326695).
3. Cysteine Reducing Reagent: 50 mM Dithiothreitol (DTT, BioRad Cat #161-0611, Hercules, CA, USA). Cysteine.
4. Alkylation Reagent: 50 mM Iodoacetamide (IAM, BioRad Cat # 163-2109, Hercules, CA, USA).
5. Eppendorf Vacufuge concentrator 5301 (Eppendorf North America, Inc. Westbury, NY, USA).

### 2.3 iTRAQ Labeling

1. Reducing Reagent: 50 mM Tris-(2-carboxyethyl) phosphine (TCEP).
2. Cysteine-Blocking Reagent: 200 mM methyl methanethiosulfonate (MMTS).
3. HPLC grade ethanol.
4. HPLC grade water.
5. Trypsin (20 µg/vial, Promega, cat no. V5111, Madison, WI, USA).
6. iTRAQ™ reagents: 114, 115, 116, 117, (Applied Biosystems Inc., ABI, Forster City, CA, USA).

	7. Eppendorf Vacufuge concentrator 5301 (Eppendorf North America, Inc. Westbury, NY, USA).	130 131
<b>2.4 Liquid Chromatography Systems</b>		
<i>2.4.1 Strong Cation Exchange Liquid Chromatography</i>	1. Mobile Phase A: 10 mM $\text{KH}_2\text{PO}_4$ and 20 % acetonitrile (ACN), pH 3.0.	132 133
	2. Mobile Phase B: 600 mM KCl, 10 mM $\text{KH}_2\text{PO}_4$ and 20 % ACN, pH 3.0.	134 135
	3. BioCAD Sprint™ Perfusion Chromatography System (PerSeptive BioSystems).	136 137
	4. Column: Polysulfoethyl-A column (4.6×200 mm, 5 μm, 300 Å, Poly LC Inc., Columbia, MD, USA).	138 139
<i>2.4.2 Peptide Desalting</i>	1. PepClean C <sub>18</sub> spin columns (Pierce, cat #. 89870, Rockford, IL, USA).	140 141
	2. Loading Solution: 5 % ACN containing 0.5 % trifluoroacetic acid (TFA, Pierce, cat # 28904, Rockford, IL, USA).	142 143
	3. Activation Solution: 50 % ACN containing 0.5 % TFA.	144
	4. Elution Solvent: 70 % ACN.	145
	5. Eppendorf Vacufuge concentrator 5301 (Eppendorf North America, Inc. Westbury, NY, USA).	146 147
<i>2.4.3 Reversed-Phase Liquid Chromatography</i>	1. Mobile Phase A: 5 % ACN containing 0.1 % TFA.	148
	2. Mobile Phase B: 95 % ACN containing 0.1 % TFA.	149
	3. LC-Packings Ultimate Chromatography System equipped with a Probot MALDI spotting device (Dionex, Sunnyvale, CA, USA).	150 151 152
	4. C <sub>18</sub> PepMap trapping column (0.3×5 mm, 5 μm, 100 Å, Dionex, P/N 160454).	153 154
	5. C <sub>18</sub> PepMap capillary column (0.1×150 mm, 3 μm, 100 Å, Dionex, P/N 160321).	155 156
	6. Matrix-Assisted Laser Desorption Ionization (MALDI) Matrix Solution: 7 mg/ml α-cyano-4-hydroxycinnamic acid (Sigma, cat #. 476870, St Louis, MO, USA) in 60 % ACN, 5 mM ammonium monobasic phosphate and internal peptide calibrants (50 fmol/ml each of (Glu1)-fibrinopeptide B (GFP, <i>m/z</i> 1,570.677, Sigma, cat #. F3261) and adrenocorticotrophic hormone 18–39 (ACTH 18–39, <i>m/z</i> 2,465.199, Sigma, cat #. A8346)).	157 158 159 160 161 162 163 164
<b>2.5 Mass Spectrometry</b>	1. 4800 Proteomics Analyzer (ABI).	165
	2. MALDI plates (ABI).	166
	3. Mass Standards Kit containing a six-peptide mixture (ABI, cat# 4333604).	167 168

169 **2.6 Data Analysis**  
170 **Software**

1. 4000 Series Explorer (ABI).
2. GPS Data Explorer v3.5 (ABI).
3. Mascot Search Engine v1.9 (Matrix Science Ltd. London, UK).

172 **3 Methods**

173 **3.1 Protein**  
174 **Extraction**

1. Mouse left ventricular tissues (~100 mg) are diced into 2 × 2 mm cubes and wash thoroughly by ice-cold PBS (repeat twice) to remove blood content in a 2 ml Eppendorf tube.
2. Spin down heart tissues and remove supernatant.
3. Add 500 µl of either ICAT or iTRAQ lysis buffer to each sample tube (see Note 2).
4. Perform heart tissue homogenization on an Omni Tissue Homogenizer at 4 °C. Six strike cycles (15 s each) were carried out with 2 min cooling interval to avoid overheating (see Note 3).
5. Remove tissue debris in the homogenates by centrifugation for 30 min at 14,000 × g at 4 °C in a bench-top centrifuge. Transfer supernatants into a fresh 1.5 ml Eppendorf tube and keep it on ice.
6. Measure protein concentrations for all six samples using the BCA protein assay with bovine serum albumin (BSA) diluted in the lysis buffer as standards. Protein yield will be in the range of 4–10 mg/ml depending on the lysis buffer of choice.
7. Adjust protein concentration of each sample to the same level with either ICAT or iTRAQ lysis buffer.

192 **3.2 ICAT Labeling**

1. Pipette 120 µg protein from each sample into separate tubes (see Note 4).
2. Precipitate protein in cold acetone (5:1 ratio at -20 °C) overnight (see Note 5).
3. Pellet protein content by high-speed centrifugation for 15 min at 14,000 × g at 4 °C.
4. Remove supernatant and wash the pellets three times with cold acetone (-20 °C).
5. Solubilize protein with 80 µl of ICAT-labeling buffer: 6 M urea, 2 % CHAPS, 0.01 % SDS, and 30 mM Tris-HCl at pH 8.3 (see Note 6).
6. Bring the ICAT reagent tubes to room temperature and briefly spin down the powder to the bottom of the tubes.
7. Add 20 µl of ACN to each ICAT tube and vortex the solution.
8. Spin down the solution to the bottom of the tubes and transfer the entire content to designated sample tubes for protein labeling.



9. Incubate the mixture for 2 h at 37 °C. 209
10. Briefly centrifuge to bring all the solution to the bottom of each tube. 210  
211
11. Quench excess ICAT reagents by adding 10 mM DTT (final concentration) and incubate for 15 min (see Note 7). 212  
213
12. Alkylate newly generated sulfhydryls by 15 mM IAM (final concentration) and incubate for 15 min at room temperature in dark (~~see Note 8~~). 214  
215  
216
13. Mix light and heavy ICAT-labeled sample pairs. 217
14. Dilute the sample volume at least 6 times with 20 mM ammonium bicarbonate buffer (see Note 9). 218  
219
15. Add trypsin solution to a final 1:50 ratio (enzyme: protein) and digest overnight at 37 °C (see Note 8). 220  
221
16. Dry the digested peptide samples in a speedvac. 222

[AU3]

### 3.3 SCX-LC

The combined peptide mixture was separated by strong cation exchange liquid chromatography (SCX-LC) on a polysulfoethyl-A column to remove excess ICAT reagents and unwanted detergent (SDS and CHAPS), prior to fractionation of the peptides. 223  
224  
225  
226

1. Reconstitute the ICAT-labeled peptides by adding ~500 µl of SCX Mobile Phase A. Adjust pH to 2.5–3.0 with phosphoric acid if necessary. 227  
228  
229
2. Centrifuge the sample at 20,000 × g for 10 min to remove any particulates. 230  
231
3. Equilibrate the SCX column with Mobile Phase A, and then inject the ICAT-labeled peptides onto the SCX column through a 500 µl sample loading loop. 232  
233  
234
4. The gradient profile of SCX consisted of 10 min of 100 % Mobile Phase A followed by 30 min of 0–25 % Mobile Phase B and 20 min of 25–100 % B at 1 ml/min. Collect peptide fractions at 2 min/fraction after the elution of neutral and anionic interference. 235  
236  
237  
238  
239
5. Dry all the SCX fractions in a speedvac for subsequent desalting steps. 240  
241

### 3.4 Peptide Desalting Using C<sub>18</sub> Spin Columns

1. Reconstitute each dried SCX fraction in 150 µl of the Loading Solution (see Note 10). 242  
243
2. Add 200 µl of the Activation Solution into a C<sub>18</sub> spin column and centrifuge at 1,500 × g for 1 min. Repeat this step once. 244  
245
3. Equilibrate the spin column with 200 µl of the Loading Solution and centrifuge the column at 1,500 × g for 1 min. Repeat this step twice. 246  
247  
248
4. For each SCX fraction, load 150 µl of the peptides in the Loading Solution onto the spin column and centrifuge at 249  
250

- 251 1,000×g for 1 min and collect the flow through. Reload the  
252 flow through materials onto the spin column.
- 253 5. Wash the bound peptides with 200 µl of the Loading Solution  
254 and centrifuge at 1,500×g for 1 min to remove salts. Repeat  
255 this step twice.
- 256 6. Elute the peptides using 100 µl of the Elution Solution by  
257 centrifugation at 1,500×g for 1 min and repeat twice. Collect  
258 all three eluants into the same Eppendorf tube.
- 259 7. Dry the peptides solution in a ~~speedvac~~.

260 **3.5 Enrichment of**  
261 **ICAT-Labeled Peptides**  
262 **by Avidin Affinity**  
263 **Chromatography**

- 264
- 265 1. Reconstitute each dried peptide fraction in 500 µl of the  
266 Affinity-Load Buffer, vortex to mix the solution. Confirm the  
267 pH of solution is ~7.0 (see Note 11).
- 268 2. Briefly centrifuge to bring all the solution to the bottom of the  
269 tubes.
- 270 3. Assemble avidin cartridge system.
- 271 4. Load 2 ml Affinity-Elution Buffer to the cartridge and discard  
272 the eluate.
- 273 5. Load 2 ml Affinity-Load Buffer to the cartridge and discard  
274 the eluate.
- 275 6. Slowly load (drop by drop) the peptide samples in 500 µl of  
276 the Affinity-Load Buffer and collect the flow through (see  
277 Note 12).
- 278 7. Reload the flow on the avidin cartridge and ~~collect~~ the flow  
279 through.
- 280 8. Wash the avidin cartridge with 1 ml of Wash1 and divert the  
281 eluate to waste.
- 282 9. Wash the avidin cartridge with 1 ml of Wash2 and divert the  
283 eluate to waste.
- 284 10. Wash the avidin cartridge with 1 ml of ~~Milli-Q~~ water and divert  
285 the eluate to waste.
- 286 11. Load 800 µl of Affinity-Elution Buffer into syringe and inject  
287 slowly to the cartridge (~1 drop/5 s) and discard the first 50 µl  
288 of eluate. Collect the remaining 750 µl of eluate into a glass  
289 vial.
- 290 12. Repeat steps 1–11 for the remaining peptide fractions.

286 **3.6 TFA Cleavage**  
287 **of Biotin Moiety**  
288 **from ICAT Peptides**

- 289 1. ~~Speedvac~~ the affinity eluates to complete dryness (see Note 13).
- 290 2. Prepare cleavage mixture of 95 µl of cleavage reagent A with  
291 5 µl of cleavage reagent B and mix them with dry peptide  
samples.
3. Vortex the reaction mixture and incubate at 37 °C for 2 h.
4. Centrifuge and dry the reaction mixtures.

### 3.7 RPLC and Spotting MALDI Plate

1. Reconstitute cleaved ICAT peptide samples in 20  $\mu$ l of RPLC Mobile Phase A (MPA), vortex vigorously, then centrifuge at 10,000  $\times g$  for 5 min. 292  
293  
294
2. Equilibrate the RPLC column with 5 % RPLC Mobile Phase B for at least 15 min for stable column pressure. 295  
296
3. Each fraction (6.4  $\mu$ l) will be loaded onto a C<sub>18</sub> trapping column using a Microliter Pickup method at a flow rate of 20  $\mu$ l/min. Online desalting step was carried out by a 5-min MPA wash. 297  
298  
299  
300
4. Peptides bound to the trapping column are subsequently resolved on a C<sub>18</sub> capillary PepMap column with the following gradient profiles at a flow rate of 400 nl/min (Table 1). 301  
302  
303
5. Mix the RPLC eluants in line with MALDI matrix in a 1:2 ratio through a 30 nl mixing tee, and deposited onto a MALDI plate using the Probot, at 12 s per spot. 304  
305  
306
6. Repeat the RPLC steps for each SCX fraction. 307

### 3.8 Mass Spectrometry

1. Mix 50 fmol of 6-peptide calibrants at a ratio of 1:1 with MALDI matrix solution. Deposit the freshly prepared calibrant solution on the calibration spots on the MALDI plate. 308  
309  
310
2. Create a new spot set and load and align the ICAT sample plates. Load the sample plates into the plate loader of the 4800 Proteomics Analyzer. 311  
312  
313
3. Acquire and update the MS calibration file using the six-peptide mixture in the Mass Standards Kit. The MS/MS calibration file needs to be updated using GFP MS/MS ions ( $m/z$  1,570.677). 314  
315  
316  
317
4. Acquire MS spectra for each spot in the positive ion mode with a laser intensity of 3,200 and mass range of 850–3,500 and sum of the first 1,500 laser shots. In the MS processing method, 318  
319  
320

**Table 1**  
**Gradient profiles for C<sub>18</sub> PepMap column (flow rate: 400 nl/min)**

Time (min)	Solvent A	Solvent B	
0	95	5	t1.3
2	95	5	t1.4
75	70	30	t1.5
90	10	90	t1.6
100	10	90	t1.7
105	95	5	t1.8
115	95	5	t1.9
			t1.10

321 use internal calibration standards (GFP ( $m/z$  1,570.677) and  
322 ACTH 18–39 ( $m/z$  2,465.199)) to achieve a mass accuracy  
323 better than 50 ppm.

324 5. After MS analysis, identify and extract ICAT ion pairs ( $\Delta m/z$   
325  $9.03 \pm 0.03$  Da) by GPS Explorer software (v3.5 ABI).  
326 Compute the relative ICAT ratios with the integrated chro-  
327 matographic areas of each ICAT ion pair. Submit ICAT pair  
328 with over 20 % change ratio and signal/noise ratio ( $S/N$ ) > 50  
329 to MS/MS acquisition (see Note 14).

[AU4] 330 6. In the MS/MS acquisition method, spectra are accumulation  
331 of 2,000 laser shots at a laser intensity of 3,200 using 2-keV  
332 collision energy and  $5 \times 10^{-7}$  Torr collision gas pressure.  
333 Generate peak lists with 4000 Series Explorer with the follow-  
334 ing settings: set  $S/N$  threshold to 10, local noise window width  
335 at 250  $m/z$ , and minimum peak width bin size was 2.9; set  
336 resolution at 22,000 at  $m/z$  2,400 for MS and 8,000 at  $m/z$   
337 2,000 for MS/MS. Smooth MS/MS spectra with the Savitzky-  
338 Golay algorithm (FWHM = 9, polynomial order = 4).

### 339 3.9 Database Search

- 340 1. Perform peptide identification on a MASCOT search engine  
341 (v1.9) integrated in the GPS Explorer software with the  
342 following search parameters: one missed tryptic cleavage,  
343 50 ppm for MS mass error tolerance, and 0.3 Da for MS/MS  
344 mass error tolerance, variable modifications included ICAT  
345 L/H modifications, carbamidomethylation of cysteines, and  
346 methionine oxidation.  
347 2. Unique peptides with confidence interval (C.I.) values above  
348 95 % from the MS/MS search are considered significant (see  
Note 15).

### 349 3.10 Trypsin 350 Digestion and iTRAQ 351 Labeling

- 352 1. Pipette 100  $\mu\text{g}$  of protein from the four samples into four sepa-  
353 rate tubes (see Note 16). To each sample, add 2  $\mu\text{l}$  of reducing  
354 reagent and vortex. Bring down the contents with a brief cen-  
355 trifugation. Incubate the sample tubes at 60 °C for 1 h. Spin  
356 briefly to settle the liquid to the bottom of each tube.  
357 2. To each sample, carefully add 1  $\mu\text{l}$  of the cysteine blocking  
358 reagent. Mix by vortexing and centrifuge briefly to collect the  
359 solutions at the bottom of the tube. Incubate at room  
360 temperature for 10 min.  
361 3. Reconstitute two vials of trypsin (20  $\mu\text{g}/\text{vial}$ ) with 25  $\mu\text{l}$  each  
362 of HPLC grade water. Vortex briefly.  
363 4. To each sample tube, add 10  $\mu\text{l}$  of the trypsin solution, vortex,  
364 and centrifuge briefly to collect the solution at the bottom of  
365 the tube. Incubate at 37 °C for 12–16 h. Spin briefly to bring  
the sample solution to the bottom of the tubes (see Note 17).  
5. Bring the iTRAQ reagents to room temperature. Add 70  $\mu\text{l}$  of  
ethanol into each reagent vial, cap the vial and vortex vigorously,

- and then centrifuge briefly to settle the iTRAQ reagents to the bottoms of the vials (see Note 18).
6. Transfer the entire content of one iTRAQ reagent vial into each of the four sample tubes, and vortex to mix thoroughly. Spin briefly to collect the liquid at the bottom of the tubes. Peptides derived from the two control samples are labeled with iTRAQ Reagents 114 and 115, whereas peptides obtained from the two ~~Trx1-overexpressed~~ samples are labeled with iTRAQ Reagents 116 and 117. Incubate the reaction vials at room temperature for 1 h.
  7. Carefully combine the entire contents of all four iTRAQ-labeled samples into one tube, mix thoroughly by vortexing, and then centrifuge briefly.
1. The combined peptide mixture ~~will be~~ first separated by SCX-LC to remove excess iTRAQ reagents. In order to remove both TEAB and the organic solvent from the sample, dry the combined sample completely in a ~~vacuum concentrator~~ (see Note 19). Follow the same steps in Subheading 3.3 to fractionate the peptides.
  2. Follow the same steps in Subheading 3.4 to desalt the peptides. Dry the resulting peptides by ~~speedvac~~ and reconstitute the peptides with 10  $\mu$ l ~~Solvent A~~. Use Nano-RPLC for peptide separations following the same steps in Subheading 3.7, except using the following gradient: (Table 2).
  3. Mix the RPLC eluants in line with MALDI matrix and deposited onto a MALDI plate. Follow steps 1–3 in Subheading 3.8 to calibrate the 4800 MALDI TOF/TOF analyzer.

### 3.11 2D-LC Separation and MS Analysis

**Table 2**

**Gradient profile for Nano-RPLC column (~~C<sup>18</sup> Capillary PepMap~~) used to ~~separate the combined~~ peptide mixture (~~all four iTRAQ samples~~)**

Time (min)	Solvent A	Solvent B
0	95	5
4	92	8
34	82	18
57	62	38
64	5	95
69	5	95
70	95	5
85	95	5

- 393  
394  
395  
396  
397  
[AU5]398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414
4. Create an acquisition, a processing, and a job-wide interpretation method for both MS and MS/MS analyses. Use the MS acquisition method in a positive MS reflector with a mass range of 850–3,000 (in Da) and a focus mass of 1,950 Da. Set the laser intensity to 3,000 and the detector voltage multiplier at 0.90. ~~Average MS spectrum over 1,000 laser shots.~~ In the processing method, GluFib ( $m/z$  1,570.677) and ACTH 18–39 ( $m/z$  2,465.199) masses are used as the internal calibrants.
  5. For the interpretation method, the precursor selection is based on a minimum S/N filter of 50, precursor mass tolerance of 200 ppm, ~~and from weakest to strongest peaks as an MS/MS acquisition order.~~
  6. Use a 2 kV positive MS/MS method. Set the laser intensity to 4,000 and detector voltage multiplier at 0.90. Specify the metastable suppression as “on” and the precursor mass window at relative 400 resolution (FWHM). Each MS/MS spectrum is accumulated over 4,000 laser shots. In the MS/MS processing method, each spectrum is smoothed using the Savitzky–Golay algorithm with points across the peak set at 3 and polynomial order set at 4. Set the medium CID gas recharge pressure to medium with a threshold of  $5.0 \times 10^7$  Torr.

### 415 **3.12 Bioinformatics**

#### 416 **Analysis**

- 417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437
1. Peptide identification is performed by searching the MS/MS spectra against Swissprot mouse database (see Note 20), using a local MASCOT search engine (v. 1.9) on a GPS (v. 3.5, ABI) server. The following search parameters are used: trypsin with one missed cleavage, mass tolerance of 50 ppm for the precursor ions, and 0.3 Da for the MS/MS fragment. iTRAQ-labeled N-terminal and lysine and cysteine methanethiolation were selected as fixed modifications, while methionine oxidation and iTRAQ-labeled tyrosine were considered as variable modifications. Only peptides identified with confidence interval (C.I.) values greater than 95 % should be used for protein identification and quantitation.
  2. Extract the iTRAQ reporter ions cluster areas using GPS Explorer. Only ion counts greater than 5,000 are used for quantification analysis. The individual reporter ion peak areas for each iTRAQ channel are normalized by the population median.
  3. For each peptide, the ratio of normalized reporter ion peak areas at 115, 116, and 117 are divided by the normalized reporter ion peak areas at 114. Such ratios are then transformed into  $\log_2$  values. In cases of multiple MS/MS spectra matched to the same peptide sequence, the peptide ratio is calculated and weighted based on the relative proportion of each spectrum.

[AU6]

4. The mean of all peptide ratios from the same protein are calculated. The relative protein expression between Tg-Trx and control samples are computed based on the following equation: 438  
439  
440  
441

$$P_i = \frac{(P_{116i} + P_{117i})}{2} - \frac{(P_{114i} + P_{115i})}{2} \quad 442$$

~~$P_i$ : the pooled protein  $\log_2$  ratio of the  $i$ th protein ( $i=1, 2, 3, \dots, N$ , where  $N$  is the total number of identified proteins).~~ 443  
444

5. The  $p$ -values in Student's t-tests are calculated by comparing each protein  $\log_2$  ratio in the control group ( $P_{114}$  and  $P_{115}$ ) to those in the Tg-Trx group ( $P_{116}$  and  $P_{117}$ ) using Microsoft Excel. Anti- $\log_2$  of  $P_i$  values is calculated to produce the exact protein fold change values. 445  
446  
447  
448  
449

---

#### 4 Notes 450

1. It is recommended to use freshly prepared lysis buffer. Selection of proper detergents is discretionary upon protein of interest (e.g., membrane proteins). 451  
452  
453
2. To preserve the native redox states of protein cysteines, it is highly recommended to minimize sample exposure to air, keep samples on ice during sample preparation if compatible, and purge with high-purity nitrogen for extended incubation (e.g., trypsin digestion step). 454  
455  
456  
457  
458
3. Depending on the detergents of choice, excessive bubbles may be formed in the lysis process. A quick spin-down of sample tubes at 4 °C will help to remove bubbles. 459  
460  
461
4. Estimate free protein thiol content in the samples. For example, for 100  $\mu$ g protein with an average mass of 50 kDa and 6 cysteines per protein, the total cysteine content can be estimated as  $100 \times 10^{-6} \text{ g} / 50,000 \text{ g/mol} \times 6 = 12 \text{ nmol}$ . Each ICAT tube contains 175 nmol of labeling reagent to maintain excessive reagent/free cysteines ratio >10 times for complete labeling. 462  
463  
464  
465  
466  
467  
468
5. Whole cell lysates contain many small molecules that could have adverse effects on protein ICAT labeling. For example, glutathione and other cysteine-containing antioxidants are observed at high levels (mM) and will consume ICAT reagents at much faster reaction rates than protein thiols. Alternative precipitation methods (such as TCA precipitation and methanol/chloroform precipitation) and buffer exchange methods (membrane ultrafiltration) can be implemented to remove interfering molecules. 469  
470  
471  
472  
473  
474  
475  
476  
477


- 478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488
6. To avoid protein loss and sample variation, complete solubilization of proteins is a key step. Mild agitation with Eppendorf pipette tips and sonication in a water bath will facilitate protein solubilization. Increasing SDS concentration to 0.05 % can also enhance the degree of protein solubilization.
- 489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499
7. In addition to scavenging excess ICAT reagents, DTT also reduces disulfide bonds and other reversible cysteine modifications. This is important in the forward redox ICAT-labeling scheme, since the reduction of disulfide bonds (~~omit before ICAT labeling~~) will facilitate tryptic digestions and improve protein and peptide identifications.
- 500  
501  
502  
503  
504  
505  
506  
507  
508  
509
8. ~~Aliquot 1 µl of solution from each reaction mixture (step 13) and 1 µl of solution before and after tryptic digestion for as a quality control step.~~ Load the samples in separate lanes of ID-SDS PAGE. After electrophoresis and protein staining, evaluate the initial sample loading and digestion efficiency. In the second QC test, mix 1 µl each of tryptic heavy and light ICAT-labeled peptides, ~~desalt with ZipTip and spot the sample~~ at 1:1 ratio with MALDI matrix solution on a MALDI plate. Acquire MS spectrum of the peptides and evaluate the abundance and relative ratio of ICAT pairs with 9 Da (or multiplier) mass differences.
- 510  
511  
512
9. Reducing urea concentration to <1 M is important for effective trypsin digestion. It is also important to adjust the pH of the solution to ~~the~~ range of 8.0–8.5 for optimum trypsin activity.
- 513  
514  
515  
516
10. Combining adjacent fractions with less peptide abundance according to the SCX chromatogram greatly reduces the ~~sample~~ processing time without much loss of total protein identification and quantification. Late-eluted fractions might have more salts and require additional loading buffer for full dissolution.
- 517  
518  
519  
520  
521  
522  
523
11. The loading capacity of the avidin cartridge is ~10 µg of peptide. A new avidin cartridge can be used up to 50 times with proper usage and storage.
12. Using a syringe pump (e.g., Standard Infusion Only Pump 11 Elite Syringe Pumps, Harvard Apparatus, Holliston, MA, USA) for solvent delivery yields more consistent and robust results.
13. Residual water content will have an adverse effect on the cleavage reaction. It is critical to dry the peptide samples completely before TFA cleavage. Perform the reaction in a hood with proper ventilation. Since TFA is reactive and corrosive to a broad range of materials, it is suggested to use glass vials and glass syringe with metal plunger to transfer and hold the reaction mixtures.

[AU7]

[AU8]



14. Peptides containing multiple cysteines can result in multiple ICAT labeling; thus, the mass difference for these peptides may be observed in multipliers of ( $\Delta m/z$   $9.03 \pm 0.03$  Da). This can be addressed by setting allowance of multiple ICAT labeling in the GPS Explorer software.
15. One-hit-wonder is one of the caveats in using ICAT-labeled peptides for protein identification and quantifications, given the low observation frequency of cysteines ( $< 3.3$  %) in vertebrate proteomes. It is not uncommon to find only one ICAT-labeled peptide for a given protein. Careful inspection of MS and MS/MS spectra for positive identification and removal of potential interference is important to reduce false-positive results. One confirmative hallmark for ICAT-labeled peptide is the signature mass differences of 339.1 for heavy ICAT labeled and 330.1 for light ICAT labeled, between  $y_n$  and  $y_{n-1}$  ions, where  $n$  indicates the location of ICAT-labeled cysteine (Fig. 2).
16. Based on iTRAQ instructions from ABI, each protein sample should be between 5 and 100  $\mu\text{g}$  for each iTRAQ-labeling reaction. To ensure maximum labeling efficiency, sample volumes should be less than 50  $\mu\text{l}$  each. If the sample volume is larger than 50  $\mu\text{l}$ , a speedvac can be used to reduce the sample volume before iTRAQ labeling.



this figure will be printed in b/w

**Fig. 2** Peptide identification and quantitation by ICAT and iTRAQ. Panel (a) sequence of cysteine-containing peptide is identified by matching MS<sub>2</sub> fragment ion mass to the predicted theoretical fragments. The addition of 227 Da (236 Da for the heavy ICAT tag) to a cysteine residue is a hallmark of an ICAT-labeled peptide (mass difference between  $y_3$  and  $y_4$  ions). Quantitation of light and heavy labeled peptides (redox states of cysteines in this case) is computed from the precursor intensities acquired from the MS<sub>1</sub> scan (*left inset*) or from the integrated extracted ion chromatogram. (b) iTRAQ quantitation is carried out on the reporter region (mass range 114–117 for 4-plex iTRAQ) in the MS<sub>2</sub> spectra (*see inset of panel b*). The individual peak intensity of each mass reporter ion reflects the corresponding peptide/protein level in each sample. The peptide sequence is identified in a similar manner as ICAT technology. Modified from Molecular & Cellular Proteomics, 2009 (8), 1674–1687 with permission

- 546 17. It is important to check the protein digestion efficiency before  
 547 iTRAQ labeling. Take 1  $\mu$ l of each digested sample and desalt  
 548 it using a C<sub>18</sub> ZipTip (Millipore, Billerica, MA). Mix the eluted  
 549 peptides with the MALDI matrix solution in a 1:1 ratio and  
 550 spot them onto a MALDI plate. Acquire MS spectra to check  
 551 if the peptide ion signals are comparable.
- 552 18. To maximize labeling efficiency, the concentration of organic  
 553 reagents (ethanol and iTRAQ reagents) in iTRAQ-labeling  
 554 reactions should be larger than 60 % (v/v).
- 555 19. To remove all of the TEAB, reconstitute the combined iTRAQ-  
 556 labeled samples in 100  $\mu$ l of HPLC grade water and dry the  
 557 sample in a ~~vacuum concentrator~~. Repeat this step twice to  
 558 ensure all the TEAB is evaporated.
- 559 20. It is important to use the latest version of the protein database  
 560 to ensure comprehensive peptide identification. ~~Swissprot~~, IPI,  
 561 NCBI protein database, or EST (6 frame translation into pro-  
 562 tein sequences) can be used, with an increasing number of  
 563 entries and database size. Generally speaking, using bigger  
 564 databases will likely increase one's chance to match a spectrum  
 565 to a peptide sequence. However, it will also increase the odds  
 566 for random matching. We chose the Swissprot database for our  
 567 study because of its high protein sequence accuracy and low  
 568 redundancy.

---

## 569 Acknowledgements

570 The authors are grateful for the funding support from NIH/  
 571 NINDS grant ~~NS046593~~ to H.L for the support of a NINDS  
 572 NeuroProteomics Core Facility at UMDNJ-New Jersey Medical  
 573 School.









## 574 References

- 575 1. Ross PL et al (2004) Multiplexed protein quan- 590  
 576 titation in *Saccharomyces cerevisiae* using 591  
 577 amine-reactive isobaric tagging reagents. *Mol* 592  
 578 *Cell Proteomics* 3:1154–1169
- 579 2. Ong SE et al (2002) Stable isotope labeling by 593  
 580 amino acids in cell culture, SILAC, as a simple 594  
 581 and accurate approach to expression proteom- 595  
 582 ics. *Mol Cell Proteomics* 1:376–386
- 583 3. Liu T et al (2007) Identification of differentially 597  
 584 expressed proteins in experimental autoimmune 598  
 585 encephalomyelitis (EAE) by proteomic analysis of 599  
 586 the spinal cord. *J Proteome Res* 6:2565–2575
- 587 4. Gygi SP et al (1999) Quantitative analysis of 600  
 588 complex protein mixtures using isotope-coded 601  
 589 affinity tags. *Nat Biotechnol* 17:994–999
- 590 5. Fu C et al (2008) Quantitative analysis of 602  
 591 redox-sensitive proteome with DIGE and 603  
 592 ICAT. *J Proteome Res* 7:3789–3802
- 593 6. Yamamoto M et al (2003) Inhibition of endog- 604  
 594 enous thioredoxin in the heart increases oxida- 605  
 595 tive stress and cardiac hypertrophy. *J Clin Invest* 606  
 596 112:1395–1406
- 597 7. Fu C et al (2009) Elucidation of thioredoxin 607  
 598 target protein networks in mouse. *Mol Cell* 608  
 599 *Proteomics* 8:1674–1687
- 600 8. Choe L et al (2007) 8-Plex quantitation of 601  
 602 changes in cerebrospinal fluid protein expres- 603  
 603 sion in subjects undergoing intravenous immu- 604  
 604 noglobulin treatment for Alzheimer's disease. 605  
 605 *Proteomics* 7:3651–3660

- 605 9. Sethuraman M et al (2004) Isotope-coded affinity 628  
606 tag (ICAT) approach to redox proteomics: 629  
607 identification and quantitation of oxidant-sensi- 630  
608 tive cysteine thiols in complex protein mixtures. 631  
609 *J Proteome Res* 3:1228–1233 632
- 610 10. Leichert LI et al (2008) Quantifying changes 633  
611 in the thiol redox proteome upon oxidative 634  
612 stress in vivo. *Proc Natl Acad Sci USA* 635  
613 105:8197–8202 636
- 614 11. Michalski A, Cox J, Mann M (2011) More 637  
615 than 100,000 detectable peptide species elute 638  
616 in single shotgun proteomics runs but the 639  
617 majority is inaccessible to data-dependent 640  
618 LC–MS/MS. *J Proteome Res* 10:1785–1793 641
- 619 12. Washburn MP et al (2001) Large-scale analysis 642  
620 of the yeast proteome by multidimensional 643  
621 protein identification technology. *Nat* 644  
622 *Biotechnol* 19:242–247 645
- 623 13. Chenau J et al (2008) Peptides OFFGEL elec- 646  
624 trophoresis: a suitable pre-analytical step for 647  
625 complex eukaryotic samples fractionation com- 648  
626 patible with quantitative iTRAQ labeling. 649  
627 *Proteome Science* 6:9 650
14. Obad S, dos Santos N et al (2011) Silencing of 628  
microRNA families by seed-targeting tiny 629  
LNAs. *Nat Genet* 43:371–378 630
15. Ralhan R et al (2008) Discovery and verification 631  
of head-and-neck cancer biomarkers by differ- 632  
ential protein expression analysis using iTRAQ 633  
labeling, multidimensional liquid chromatog- 634  
raphy, and tandem mass spectrometry. *Mol Cell* 635  
*Proteomics* 7:1162–1173 636
16. Keshamouni VG et al (2006) Differential pro- 637  
tein expression profiling by iTRAQ–2DLC–MS/ 638  
MS of lung cancer cells undergoing epithelial- 639  
mesenchymal transition reveals a migratory/ 640  
invasive phenotype. *J Proteome Res* 5: 641  
1143–1154 642
17. Ago T et al (2006) Thioredoxin1 upregulates 643  
mitochondrial proteins related to oxidative 644  
phosphorylation and TCA cycle in the heart. 645  
*Antioxid Redox Signal* 8:1635–1650 646
18. Yang Y et al (2011) Thioredoxin 1 negatively 647  
regulates angiotensin II-induced cardiac hyper- 648  
trophy through upregulation of miR-98/let-7. 649  
*Circ Res* 108:305–313 650

# Author Queries

Chapter No.: 15      0001913086

Queries	Details Required	Author's Response
AU1	Please check sentence starting "Unlike stable isotope..." for completeness.	
AU2	Both "Mascot Search Engine" and "MASCOT search engine" have been used in text. Please check if one form should be made consistent.	
AU3	Please check if all occurrences of "speedvac" should be changed to "SpeedVac."	
AU4	Please check sentence starting "In the MS/MS..." for completeness.	
AU5	Please check if edit to sentence starting "Average MS spectrum..." is okay.	
AU6	Please check if all occurrences of "Swissprot" should be changed to "Swiss-Prot."	
AU7	Please check sentence starting "Aliquot 1 µl of solution..." for completeness.	
AU8	Should "step 13" be "Note 13" in the sentence "reaction mixture (step 13)"? Please check.	

Uncorrected Proof